Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting

2022-502548-12-00 marginal zone lymphoma 5 2023-09-28
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Recruiting

2022-500275-31-00 Haemophilia A 5 2023-06-20
A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting

2024-510635-21-00 warm autoimmune haemolytic anaemia (wAIHA) 5 2023-05-09
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 International Prognostic Scoring System-Revised (IPSS-R 10 2023-03-28
A Study of AG-946 in Participants With Anaemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS). Recruiting

2022-500609-42-00 Anemia Due to Lower-Risk Myelodysplastic Syndromes 4 2023-02-24
A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Recruiting

2022-500391-62-00 Subjects with relapsed/refractory peripheral T-cell lym 9 2023-01-19
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting

2022-503012-16-00 Patients on treatment with Factor Xa Inhibitor needing 5 2022-07-20
Study to Evaluate how effective and safe the investigationall product, Mitapivat, is when administred to Pediatric Subjects With Pyruvate Ki… Recruiting

2024-515025-28-00 Pyruvate Kinase Deficiency 5 2022-05-24
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting

2023-505638-82-00 Atypical Hemolytic Uremic Syndrome (aHUS) 5 2022-01-12
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting

2024-515654-25-00 Relapsed and/or Refractory Chronic Lymphocytic Leukemia 9 2021-12-20
A single arm study to evaluate the safety and biological activity of pegcetacoplan in patients 12- 17 years old with paroxysmal nocturnal he… Recruiting

2024-516350-22-00 Paroxysmal Nocturnal Hemoglobinuria 4 2021-10-22
Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Recruiting

2023-508883-31-00 Solid tumors and hamatological malignancies 5 2021-02-23
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting

2023-504694-20-00 pediatric CD22-positive relapsed/refractory Acute Lymph 9 2017-01-13
ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting

2024-512657-24-00 Acute Lymphoblastic Leukaemia 10 2014-03-27
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe He… Recruiting

2023-505805-18-00 Hemophilia B 5 2026-05-27
Phase 2 Study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea. Recruiting

2025-523864-19-00 Essential Thrombocythemia 4 2026-04-23
A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people Recruiting

2025-525025-12-00 Iron overload from thalassemia, transfusion-dependent m 3 2026-04-10
Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting

2025-521286-27-00 Immune-mediated thrombocytopenia, Autoimmune thrombocyt 10 2026-03-26
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Dis… Recruiting

2024-513750-30-00 Sickle Cell Disease 4 2026-03-25
Zanubritnib and anti-MAG neuropathy Recruiting

2025-523091-23-00 Peripheral anti-MAG neuropathy, waldenstrom macroglobul 4 2026-03-24
Phase 3 study of VGA039 prophylaxis in adolescent and adult patients with von Willebrand Disease Recruiting

2025-522056-10-01 von Willebrand Disease 5 2026-03-19
Single-center phase I/IIa study with CART cells produced using the anti-CD19 transposon technique (TranspoCART19) for patients with CD19+ ac… Recruiting

2025-522673-11-00 refractory or resistant CD19+ acute lymphoblastic leuke 9 2026-03-17